In Vitro hydrodynamic evaluation of prosthetic polymer heart valves in steady flow

KSME Journal ◽  
1993 ◽  
Vol 7 (3) ◽  
pp. 223-230
Author(s):  
B. C. Pak ◽  
B. S. Cho ◽  
B. J. Baek ◽  
C. S. Kim ◽  
B. G. Min
Keyword(s):  
Steady Flow ◽  
Heart Valves ◽  
Hydrodynamic Evaluation

Computational Prediction of Fluid Induced Stress States in Dynamically Conditioned Engineered Heart Valve Tissues

2012 ◽  
Author(s):  
M. Salinas ◽  
D. Schmidt ◽  
R. Lange ◽  
M. Libera ◽  
S. Ramaswamy
Keyword(s):  
Shear Stress ◽  
Steady Flow ◽  
Heart Valve ◽  
Heart Valves ◽  
Critical Role ◽  
Computational Prediction ◽  
Mechanical Conditioning ◽  
Custom Made ◽  
Stress Environments

There is extensive documented evidence that mechanical conditioning plays a significant role in the development of tissue grown in-vitro for heart valve scaffolds [1–3]. Modern custom made bioreactors have been used to study the mechanobiology of engineered heart valve tissues [1]. Specifically fluid-induced shears stress patterns may play a critical role in up-regulating extracellular matrix secretion by progenitor cell sources such as bone marrow derived stem cells (BMSCs) [2] and increasing the possibility of cell differentiation towards a heart valve phenotype. We hypothesize that specific biomimetic fluid induced shear stress environments, particularly oscillatory shear stress (OSS), have significant effects on BMSCs phenotype and formation rates. As a first step here, we attempt to quantify and delineate the entire 3-D flow field by developing a CFD model to predict the fluid induced shear stress environments on engineered heart valves tissue under quasi-static steady flow and dynamic steady flow conditions.

500 An in vitro steady flow model of mitral regurgitation by three-dimensional Doppler

1999 ◽  
Vol 1 ◽  
pp. S86-S86
Author(s):  
R DESIMONE ◽  
G GLOMBITZA ◽  
C VAHL ◽  
H MEINZER ◽  
S HAGL
Keyword(s):  
Mitral Regurgitation ◽  
Steady Flow ◽  
Flow Model ◽  
Three Dimensional

The Effect of Dipyridamole and RA 233 on Human Platelet Function in Vitro

1973 ◽  
Vol 29 (03) ◽  
pp. 694-700 ◽  
Author(s):  
Paul L. Rifkin ◽  
Marjorie B. Zucker
Keyword(s):  
Mechanism Of Action ◽  
Human Blood ◽  
Glass Bead ◽  
Heart Valves ◽  
Human Platelet ◽  
Drug Effects ◽  
Simple Relation ◽  
Prosthetic Heart Valves ◽  
Induced Aggregation

SummaryDipyridamole (Persantin) is reported to prolong platelet survival and inhibit embolism in patients with prosthetic heart valves, but its mechanism of action is unknown. Fifty jxM dipyridamole failed to reduce the high percentage of platelets retained when heparinized human blood was passed through a glass bead column, but prolonged the inhibition of retention caused by disturbing blood in vitro. Possibly the prostheses act like disturbance. Although RA 233 was as effective as dipyridamole in inhibiting the return of retention, it was less effective in preventing the uptake of adenosine into erythrocytes, and more active in inhibiting ADP-induced aggregation and release. Thus there is no simple relation between these drug effects.

Haemodynamic in vitro characteristics of heart valves for percutaneous applications

2007 ◽  
Vol 55 (S 1) ◽  
Author(s):  
UA Stock ◽  
T Attmann ◽  
M Hartrumpf ◽  
RU Kuehnel ◽  
M Wendt ◽  
...  
Keyword(s):  
Heart Valves

scholarly journals Heparin is more effective than apixaban in inhibiting in vitro contact activated coagulation

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M.M Engelen ◽  
C Van Laer ◽  
M Jacquemin ◽  
C Vandenbriele ◽  
K Peerlinck ◽  
...  
Keyword(s):  
Thrombin Generation ◽  
Heart Valves ◽  
Thrombus Formation ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Factor Xa ◽  
Coagulation Factor ◽  
Mechanical Heart Valves ◽  
Contact Activation

Abstract Introduction Contact of blood with artificial surfaces such as mechanical support devices, catheters, and mechanical heart valves activates the contact activation (CA) pathway of coagulation. Furthermore, recent animal data and clinical studies suggest a more important contribution of CA in pathological thrombus formation in other cardiovascular diseases. Direct oral anticoagulants (DOACs) are recommended as first-line treatment in most patients who require long-term anticoagulation. However, because DOACs directly inhibit a single downstream coagulation factor (thrombin (fXIIa) or factor Xa (fXa)), it has been suggested that their efficacy could be reduced in the presence of strong activation of the CA pathway as compared to anticoagulants that target multiple, more upstream located coagulation factors. Purpose To compare the efficacy of a DOAC (apixaban) and heparin to suppress thrombin generation in the presence of strong CA pathway activation. Methods Pooled platelet-poor plasma was spiked with either apixaban (dissolved in DMSO and PBS) or unfractionated heparin to achieve therapeutic plasma levels. SynthASil, a commercially available mixture of phospholipids and silica, was used to stimulate the CA pathway in two different dilutions (1–80 and 5–80). Downstream coagulation was accessed by Thrombin Generation Test using Thrombinoscope by Stago and associated Thrombin Calibrator (activity 640 nM). The endogenous thrombin potential (area under the thrombin generation curve; ETP), peak thrombin generation (PTG), time to peak (ttPeak) and time to start (ttStart) were accessed. Results With decreasing concentrations of apixaban, stimulation with the lower dose SynthASil reveals an increasing ETP and PTG. As expected, ttPeak and ttStart decreased. Even supratherapeutic levels of apixaban (i.e. 1120 ng/mL) could not inhibit thrombin from being generated, in striking contrast with UFH where no thrombin was formed. Using a five times higher dose of SynthASil showed comparable ETP for all concentrations of apixaban, allocated around the control value. PTG, however, slightly increased with decreasing concentrations of apixaban. ttPeak and ttStart slightly decreased. Except for the subtherapeutic UFH concentration of 0,114 IU/mL, no thrombin was generated with UFH. Conclusion UFH is more effective in inhibiting downstream thrombin generation compared to apixaban as a response to activation of the CA pathway in vitro. These findings could help explain why direct inhibitors were not able to show non-inferiority in patients with mechanical heart valves and support the development of specific CA pathway inhibitors for patients with conditions that activate the CA pathway. Thrombin generation curves Funding Acknowledgement Type of funding source: None

Noninvasive Electromagnetic Evaluation of Bjo¨rk-Shiley Heart Valves: Lifetime Prediction

2008 ◽  
Author(s):  
Raimond Grimberg ◽  
Adriana Savin ◽  
Shiu C. Chan ◽  
Rozina Steigmann ◽  
Lalita Udpa ◽  
...  
Keyword(s):  
Eddy Current ◽  
Heart Valves ◽  
Probability Of Detection ◽  
New Method ◽  
Lifetime Prediction ◽  
Prosthetic Heart Valves ◽  
In Vitro Experiments ◽  
Current Transducer ◽  
Eddy Current Transducer

Prosthetic heart valves of the Bjork-Shiley Convexo-Concave (BSCC) type have long been used extensively in implants; however, there have been reports of cases where one component of the valves failed, leading to the demise of the patient. This paper presents a new method for noninvasive electromagnetic evaluation for this type of valve, using an eddy current transducer with orthogonal coils. In vitro experiments have shown that discontinuities of outlet strut with depths equal or larger than 0.4mm can be detected with a probability of detection (POD) of 86.4%, and in the case of discontinuities with depth equal or larger than 0.6mm with POD of 97%.

In-vitro characterization of flow through mechanical heart valves

2006 ◽  
Vol 39 ◽  
pp. S306 ◽  
Author(s):  
L.P. Dasi ◽  
H. Simon ◽  
L. Ge ◽  
F. Sotiropoulos ◽  
A. Yoganathan
Keyword(s):  
Heart Valves ◽  
Mechanical Heart Valves ◽  
In Vitro Characterization ◽  
Flow Through

Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves

2009 ◽  
Vol 101 (06) ◽  
pp. 1163-1169 ◽  
Author(s):  
Torsten Linde ◽  
Thomas Michel ◽  
Kathrin Hamilton ◽  
Ulrich Steinseifer ◽  
Ivar Friedrich ◽  
...  
Keyword(s):  
Electron Microscopy ◽  
Unfractionated Heparin ◽  
Continuous Infusion ◽  
Valve Replacement ◽  
Heart Valves ◽  
Thrombus Formation ◽  
Mechanical Heart Valve ◽  
Mechanical Heart Valves ◽  
Valve Prostheses

SummaryPrevention of valve thrombosis in patients after prosthetic mechanical heart valve replacement and heparin-induced thrombocytopenia (HIT) is still an open issue. The aim of the present in-vitro study was to investigate the efficacy of argatroban and bivalirudin in comparison to unfractionated heparin (UFH) in preventing thrombus formation on mechanical heart valves. Blood (230 ml) from healthy young male volunteers was anticoagulated either by UFH, argatroban bolus, argatroban bolus plus continuous infusion, bivalirudin bolus, or bivalirudin bolus plus continuous infusion. Valve prostheses were placed in a newly developed in-vitro thrombosis tester and exposed to the anticoagulated blood samples. To quantify the thrombi, electron microscopy was performed, and each valve was weighed before and after the experiment. Mean thrombus weight in group 1 (UFH) was 117 + 93 mg, in group 2 (argatroban bolus) 722 + 428 mg, in group 3 (bivalirudin bolus) 758 + 323 mg, in group 4 (argatroban bolus plus continuous infusion) 162 + 98 mg, and in group 5 (bivalirudin bolus plus continuous infusion) 166 + 141 mg (p-value <0.001). Electron microscopy showed increased rates of thrombus formation in groups 2 and 3. Argatroban and bivalirudin were as effective as UFH in preventing thrombus formation on valve prostheses in our in-vitro investigation when they were administered continuously. We hypothesise that continuous infusion of argatroban or bivalirudin are optimal treatment options for patients with HIT after mechanical heart valve replacement for adapting oral to parenteral anticoagulation or vice versa.

Sign in / Sign up

Export Citation Format

Share Document